NEW
Rexulti

Rexulti Warnings

brexpiprazole

Manufacturer:

Otsuka

Distributor:

Zuellig
Full Prescribing Info
Warnings
Increased Mortality in Elderly Patients with Dementia: Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of thirteen placebo-controlled trials with various atypical antipsychotics (modal duration of 10 weeks) in these patients showed a mean 1.6-fold increase in the death rate in the drug-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature (see Use in the Elderly: Use in Elderly Patients with Dementia under Precautions). REXULTI is not approved for the treatment of patients with dementia.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in